Hepatitis C vaccine
نویسندگان
چکیده
منابع مشابه
Hepatitis C Virus and Vaccine Development
The prevalence of Hepatitis C virus (HCV) is approximately 3% around the world. This virus causes chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. The effectiveness of interferon-α and ribavirin therapy is about 50% and is associated with significant toxicity and cost. Hence, generating new vaccines or drugs is an obligation. However, there is no vaccine available for clinical u...
متن کاملPolymer-basednanoadjuvants for hepatitis C vaccine: The perspectives of immunologists
The hepatitis C virus (HCV) is an infection that affects the liver tissues in humans, leading to the development of effective prophylactic and therapeutic HCV vaccines to prevent a global epidemic. Scientists consider it challenging to produce a therapeutic vaccine for the treatment of hepatocellular carcinoma as opposed to a preventative vaccine. However, several drawbacks are involved with a ...
متن کاملHepatitis C Virus and Vaccine Development
The prevalence of Hepatitis C virus (HCV) is approximately 3% around the world. This virus causes chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. The effectiveness of interferon-α and ribavirin therapy is about 50% and is associated with significant toxicity and cost. Hence, generating new vaccines or drugs is an obligation. However, there is no vaccine available for clinical u...
متن کاملHepatitis C vaccine approaches phase II trial.
The fi rst prophylactic hepatitis C vaccine to reach human trials could enter phase II testing this year, a landmark for a fi eld that has faced many technical challenges since the virus was identifi ed in 1989. If this vaccine — or one of several other candidates — is successful, the public health impact could be substantial. Hepatitis C is a major cause of liver disease, including hepatocellu...
متن کاملhepatitis c virus and vaccine development
the prevalence of hepatitis c virus (hcv) is approximately 3% around the world. this virus causes chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. the effectiveness of interferon-α and ribavirin therapy is about 50% and is associated with significant toxicity and cost. hence, generating new vaccines or drugs is an obligation. however, there is no vaccine available for clinical u...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Human Vaccines & Immunotherapeutics
سال: 2014
ISSN: 2164-5515,2164-554X
DOI: 10.4161/hv.29033